David R. Wood
University of Utah
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by David R. Wood.
Journal of Clinical Psychopharmacology | 1988
William F. Byerley; Fred W. Reimherr; David R. Wood; Bernard I. Grosser
In a double-blind, placebo-controlled study the authors found that fluoxetine, a potent and selective inhibitor of serotonin reuptake, was an effective antidepressant in moderately depressed, ambulatory outpatients. Typical adverse effects reported by patients treated with fluoxetine included agitation, nausea, fatigue, and insomnia. Compared to imipramine, fluoxetine was associated with fewer complaints of dry mouth, constipation, and dizziness.
Psychiatry Research-neuroimaging | 1983
Paul H. Wender; David R. Wood; Fred W. Reimherr; Mark F. Ward
Twenty-two patients who met the Utah criteria for attention deficit disorder, residual type (hyperactivity, minimal brain dysfunction in adults) received an open trial of pargyline (Eutonyl). Of these 22 patients, 13 (59%) showed a moderate to marked therapeutic response. Clinically useful features of pargyline in the treatment of attention deficit disorder, residual type are that its duration of action is greater than 24 hours and that it has not been abused. Pargyline inhibits monoamine oxidase, type B, and its therapeutic efficacy is compatible with the hypothesis that decreased phenethylaminergic function, dopaminergic function, or both play a role in the etiology of the disorder.
Psychiatry Research-neuroimaging | 1984
Frederick W. Reimherr; Paul H. Wender; Michael H. Ebert; David R. Wood
Following the hypothesis that attention deficit disorder in adults (attention deficit disorder, residual type; ADD, RT), as well as in children, is associated with decreased central dopaminergic activity, the authors measured lumbar cerebrospinal fluid monoamine metabolites in a group of adults with ADD, RT and matched control subjects. Patients were then entered into a double-blind, placebo-controlled trial of methylphenidate. It was predicted that the patients would have lower levels of homovanillic acid (HVA), the major dopamine metabolite in humans. Patients who had a significant response to methylphenidate showed a trend in this direction. Nonresponding patients had significantly higher levels of HVA than controls.
Psychiatry Research-neuroimaging | 1985
David R. Wood; Fred W. Reimherr; Paul H. Wender
Nineteen patients meeting the criteria for attention deficit disorder, residual type (adult hyperactivity), were given a 2-week double-blind crossover of DL-phenylalanine versus placebo. Thirteen subjects completed the study; the mean global rating of improvement approached significance as compared with placebo. A significant improvement was noted on mood and mood lability. The phenylalanine responders were then continued on open drug, but lost all positive benefits within 3 months. A later open trial of L-phenylalanine produced no clinical effect.
Journal of Clinical Psychopharmacology | 1985
Ph Wender; Fredrick W. Reimherr; David R. Wood; M Ward
Thirty-seven adult patients meeting the Utah criteria for attention deficit disorder, residual type, were entered into a double-blind crossover trial of methylphenidate and placebo. A moderate-to-marked therapeutic response occurred in 21 (57%) of the patients while receiving methylphenidate and in four (11%) while receiving placebo, a highly significant difference statistically and clinically. The responding patients showed significant improvement in the following areas: attentional difficulty, motor overactivity, affective lability, and impulsivity. The diagnosis of attention deficit disorder, residual type, should be considered in patients with prominent complaints of impulsivity, restlessness, emotional lability, and hot temper who do not suffer from schizophrenia or major mood disorder and do not have symptoms of schizotypal or borderline personality disorders.
Archives of General Psychiatry | 1981
Paul H. Wender; Frederick W. Reimherr; David R. Wood
Archives of General Psychiatry | 1976
David R. Wood; Frederick W. Reimherr; Paul H. Wender; Glen E. Johnson
American Journal of Psychiatry | 1985
Paul H. Wender; Fredrick W. Reimherr; David R. Wood; Mark F. Ward
American Journal of Psychiatry | 1983
David R. Wood; Paul H. Wender; Frederick W. Reimherr
Psychopharmacology Bulletin | 1984
Reimherr Fw; David R. Wood; Byerley B; Brainard J; Grosser Bi